“…Earlier work established D22 as a potent inhibitor of low-affinity/high-capacity transporters, including OCT2, OCT3, and PMAT (Gasser et al, 2009; Hayer-Zillgen, Brüss, & Bönisch, 2002; Russ, H., Gliese, Sonna, & Schömig, 1992; Russ, H. et al, 1993; Russ, H., Sonna, Keppler, Baunach, & Schömig, 1993; Russ, Hermann, Staudt, Martel, Gliese, & Schomig, 1996; Schomig, Babin-Ebell, & Russ, 1993; Shirasaka et al, 2016; Sun et al, 2014; Wang, Sun, Li, Tu, & Jiang, 2014; Zhang, Schaner, & Giacomini, 1998). In line with prior D22 action at hOCT3 (Hayer-Zillgen et al, 2002), we found that D22 was a more potent inhibitor of [ 3 H]MPP + uptake at hOCT3 (IC 50 ≈ 0.2 μM) than hOCT2 (IC 50 ≈ 10 μM) and extended this finding to hPMAT (IC 50 ≈ 1 μM).…”